Drug and Therapy Development for Triple Negative Breast Cancer

ebook

By Pravin Kendrekar

cover image of Drug and Therapy Development for Triple Negative Breast Cancer

Sign up to save your library

With an OverDrive account, you can save your favorite libraries for at-a-glance information about availability. Find out more about OverDrive accounts.

   Not today
Libby_app_icon.svg

Find this title in Libby, the library reading app by OverDrive.

app-store-button-en.svg play-store-badge-en.svg
LibbyDevices.png

Search for a digital library with this title

Title found at these libraries:

Loading...
Drug and Therapy Development for Triple Negative Breast Cancer

The first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer

In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies—including nanotherapeutics and photothermal therapies.

As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find:

  • A thorough introduction to HER receptors in breast cancers
  • Comprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer
  • Application of artificial intelligence to breast cancer diagnosis
  • New insights on the role of DNA replication stress and genome instability in breast cancer
  • Perfect for medicinal and pharmaceutical chemists, Drug and Therapy Development for Triple Negative Breast Cancer will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.

    Drug and Therapy Development for Triple Negative Breast Cancer